According to Protalix BioTherapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.40109. At the end of 2023 the company had a P/S ratio of 1.98.
Year | P/S ratio | Change |
---|---|---|
2023 | 1.98 | 36.07% |
2022 | 1.46 | 47.48% |
2021 | 0.9880 | -48.65% |
2020 | 1.92 | 116.21% |
2019 | 0.8899 | -1.84% |
2018 | 0.9065 | -81.12% |
2017 | 4.80 | -19.81% |
2016 | 5.99 | |
2015 | N/A | -100% |
2014 | 11.4 | -64.03% |
2013 | 31.6 | 124.11% |
2012 | 14.1 | -66.53% |
2011 | 42.1 | -66.86% |
2010 | 127 | -90.79% |
2009 | > 1000 | -100% |
2008 | > 1000 | |
2001 | > 1000 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Pfizer PFE | 2.90 | 107.02% | ๐บ๐ธ USA |
Neurocrine Biosciences
NBIX | 6.94 | 395.26% | ๐บ๐ธ USA |
Amicus Therapeutics
FOLD | 6.91 | 393.21% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | 1.20 | -14.63% | ๐ฎ๐ฑ Israel |